Last reviewed · How we verify
Traditional scorpion antivenom regimen
Traditional scorpion antivenom regimen is a Small molecule drug developed by Selene Guadalupe Huerta Olvera. It is currently in Phase 2 development.
At a glance
| Generic name | Traditional scorpion antivenom regimen |
|---|---|
| Sponsor | Selene Guadalupe Huerta Olvera |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of the Efficacy of Scorpion Antivenom Therapy in a Dose-response Manner, in Patients With Scorpionism (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Traditional scorpion antivenom regimen CI brief — competitive landscape report
- Traditional scorpion antivenom regimen updates RSS · CI watch RSS
- Selene Guadalupe Huerta Olvera portfolio CI
Frequently asked questions about Traditional scorpion antivenom regimen
What is Traditional scorpion antivenom regimen?
Traditional scorpion antivenom regimen is a Small molecule drug developed by Selene Guadalupe Huerta Olvera.
Who makes Traditional scorpion antivenom regimen?
Traditional scorpion antivenom regimen is developed by Selene Guadalupe Huerta Olvera (see full Selene Guadalupe Huerta Olvera pipeline at /company/selene-guadalupe-huerta-olvera).
What development phase is Traditional scorpion antivenom regimen in?
Traditional scorpion antivenom regimen is in Phase 2.